PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-52.90%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
4.11%
D&A growth of 4.11% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-59.26%
Working capital is shrinking yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
124.90%
Inventory growth of 124.90% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
No Data
No Data available this quarter, please select a different quarter.
-886.88%
Other WC usage shrinks yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
-1851.43%
Other non-cash items dropping yoy while Medical - Pharmaceuticals median is -85.02%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-394.70%
Negative CFO growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-5.26%
CapEx declines yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.61%
Growth of 1.61% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
-4.34%
Reduced investing yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
-10.00%
Debt repayment yoy declines while Medical - Pharmaceuticals median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.